Fujirebio expands its assay menu in the field of neurodegenerative diseases with the launch of the fully automated Lumipulse® G NfL CSF and Lumipulse® G NfL Blood tests

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio announced the availability of the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE® G immunoassay systems.